Removal of UroLume endoprosthesis: experience of the North American Study Group for detrusor-sphincter dyssynergia application.

Purpose: We present the experience of the North American UroLume Multicenter Study Group with removal of the UroLume endoprosthesis.

Materials And Methods: A total of 160 neurologically impaired patients were enrolled in the North American UroLume Multicenter Study Group for detrusor external sphincter dyssynergia application. Analysis was performed in 2 groups of patients in which the device was removed during insertion and after implantation, respectively.

Long-term followup of the North American multicenter UroLume trial for the treatment of external detrusor-sphincter dyssynergia.

Purpose: We determine the long-term efficacy and safety of the UroLume stent as minimally invasive treatment for external detrusor-sphincter dyssynergia in spinal cord injured men.

Materials And Methods: A total of 160 spinal cord injured men with a mean age plus or minus standard deviation of 36.3 +/- 12.

Bladder cancer risk in patients with spinal cord injury.

Bladder cancer (BC) is the fourth most common cancer in men. It is associated with several risk factors (RF), of which only a few have been evaluated in previous studies. Models incorporating only one or a severely restricted number of RFs did not predict BC well.

Polyethylene glycol versus vegetable oil based bisacodyl suppositories to initiate side-lying bowel care: a clinical trial in persons with spinal cord injury.

Introduction: Neurogenic bowel dysfunction resulting from spinal cord injury (SCI) frequently requires bowel care (BC) with stimulant suppositories for initiation of effective defecation. The excessive time required for BC and bowel complications have limited quality of life after SCI.

Objective: To test the hypothesis that: the time required for bowel care with bisacodyl suppositories can be reduced by substituting a polyethylene glycol base (PGB) for the traditional hydrogenated vegetable oil base (HVB) in the suppository.

From time dependent intermittent selfcatheterisation to volume dependent selfcatheterisation in multiple sclerosis using the PCI 5000 Bladdermanager.

The use of portable, patient controlled, ultrasound device for the measurement of the bladder volume (PCI 5000, Bladdermanager) in the management of neurogenic bladder dysfunction in Multiple Sclerosis is presented. Twenty-three patients were transferred from time dependent intermittent catheterisation to volume dependent intermittent catheterisation using this device. Evaluation of the accuracy of the measurements showed an accuracy of 91.